Mesalazine Treatment in IBS (The MIBS Study)

Irritable Bowel Syndrome Clinical Trial

— MIBS  

Official title:

Mesalazine Treatment in IBS, a Double-blind Placebo-controlled Phase II Intervention Study in Adult Patients

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01699438
• Other study ID #: SMR-2268
• Status: Completed
• Phase: Phase 2
• First received: September 16, 2012
• Last updated: February 23, 2017
• Start date: April 2012
• Est. completion date: February 2017

Study information

• Verified date: February 2017
• Source: Göteborg University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Irritable bowel syndrome (IBS) is a condition characterised by abdominal pain or discomfort in combination with altered bowel function (stool frequency and/or stool consistency), currently defined by the Rome III criteria. The current IBS definition specifies that there are no structural or biochemical abnormalities to account for the symptoms but there is growing evidence that in at least a subset of IBS patients, a discrete immune activation might be a key pathogenetic factor. The condition is prone to develop after a gastroenteritis, post-infectious IBS, and increased numbers of lymphocytes, mast cells and pro-inflammatory cytokines like Interleukin (IL)-1β, IL-6, Tumor necrosis factor (TNF)-α and a general increase in mucosal cellularity have been reported. Despite this, the efficacy of anti-inflammatory agents has been poorly investigated.

This will be a randomised, double blind, placebo-controlled, parallel-group, multi-centre study that aims to include a total of 200 subjects with irritable bowel syndrome (IBS). All subjects will be randomised to receive either 3x800 mg of mesalazine (Asacol®) or corresponding placebo once daily for a total treatment duration of 8 weeks. Males and females aged 18 to 70 years who already are diagnosed with IBS based on the Rome III diagnostic criteria and with a symptom intensity of at least moderate level; defined as an IBS Severity Scoring System (IBS-SSS) score of ≥175 at both Screening (Visit 1, Day -21±2) and Baseline (Visit 2, Day 0) will be eligible to enter the study.

Primary aim:

To assess the effect of mesalazine (Asacol®) treatment compared to placebo on global IBS symptoms: A treatment responder will be defined by answering the satisfactory relief of IBS-symptoms question "yes" at the end of at least 4 out of of 8 treatment weeks.

Secondary aims:

To assess mesalazine (Asacol®) treatment compared to placebo regarding:

1. Levels of inflammatory mediators in the rectal mucosa (e.g. neutrophil mediators, eosinophilic mediators, mast cell activity mediators and cytokines) measured by a new diagnostic tool, the Mucosal Patch Technology (MPT) by means of Enzyme-Linked Immunosorbent Assays (ELISA)

2. Effects on number of immune cells (count per high power field) and cytokine content (immunohistochemistry) in mucosal biopsies

3. Calprotectin levels in faeces (mg/kg)

4. Individual IBS symptom parameters derived from a symptom diary and also measured by IBS-SSS

Recruitment information / eligibility

• Status: Completed
• Enrollment: 211
• Est. completion date: February 2017
• Est. primary completion date: December 2016
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

• Males and females aged 18 to 70 years, both inclusive

• Subject is diagnosed with irritable bowel syndrome (IBS) prior to Screening based on the Rome III diagnostic criteria.

• Subject presents with IBS symptom intensity of at least moderate level; defined as an IBS Severity Scoring System (IBS-SSS) score of =175 at both Screening (Visit 1, Day -21±2) and Baseline (Visit 2, Day 0)

• Provision of signed informed consent

Exclusion Criteria:

• Subjects who are unable to understand the written and verbal instructions

• Presence of a systemic inflammatory disease

• Presence of other gastrointestinal diseases likely to explain the IBS symptoms

• Presence of other severe somatic disease

• Treatment with non-steroidal anti-inflammatory drugs (NSAID), opioid analgetics or acetylsalicylic acid (ASA) compounds within 7 days prior to screening (Visit 1, Day -21±2)

• Treatment with systemic antibiotics within 28 days prior to Screening (Visit 1, Day -21±2)

• Treatment with immunosuppressant drugs within 28 days prior to Screening (Visit 1, Day -21±2)

• Other significant medical treatment, which, in the opinion of the investigator, may compromise the safety and efficacy objectives of the study, within 28 days prior to Screening (Visit 1, Day -21±2)

• Previously confirmed allergy towards ASA or mesalazine

• Presence of renal disease and/or concomitant treatment with medications with potential renal side effects

• Current ongoing infection

• History of, or current, drug or alcohol dependence

• Pregnant or lactating women

• Subjects suspected not to follow instructions based on the discretion of the Investigator

• Current participation in other intervention studies

• Female subjects of childbearing potential unwilling to use adequate contraceptive measures throughout the duration of the study.

Related Conditions & MeSH terms

• Irritable Bowel Syndrome

Intervention

Drug:
• Mesalazine
2400 mg q.d. for 8 weeks
• Placebo
3 tablets q.d. for 8 weeks

Locations

Country	Name	City	State
Sweden	Sahlgrenska University Hospital	Göteborg
Sweden	Karolinska University Hospital	Huddinge
Sweden	Norrland's University Hospital	Umeå

Sponsors (9)

Lead Sponsor	Collaborator
Hans Törnblom	Alimenta AB, Haukeland University Hospital, Karolinska University Hospital, Oslo University Hospital, Sahlgrenska University Hospital, Sweden, Smerud Medical Research International AS, Sykehuset Innlandet HF, Tillotts Pharma AG

Country where clinical trial is conducted

Sweden, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Global Irritable Bowel Syndrome (IBS) symptoms	The main measurement parameter of symptom alleviation will be a weekly question regarding satisfactory relief of global IBS symptoms. A treatment responder will be defined as answering "yes" =50% of the weeks (=4 weeks)	8 weeks
Secondary	Inflammatory mediators	Measured by the Mucosal Patch Technology (MPT), e.g. neutrophil mediators (myeloperoxidase (MPO)), eosinophilic mediators (eosinophil cationic protein (ECP)), mast cell activity mediators (tryptase) and cytokines (Interleukin (IL)-2, IL-6, Tumor necrosis factor (TNF)-alpha, IL-1beta etc) by Enzyme-Linked Immunosorbent Assays (ELISA), (ug/ml).	8 weeks
Secondary	Effect on immune cells and cytokines in mucosal biopsies	Counts per high-power field in microscopy and by immunohistochemistry	8 weeks
Secondary	Levels of calprotectin in faeces	Enzyme-Linked Immunosorbent Assay (ELISA), mg/kg	8 weeks
Secondary	Change in total IBS symptom severity score (IBS-SSS)	Absolute change in IBS-SSS compared to baseline.	8 weeks
Secondary	Individual symptom parameters in IBS symptom severity score (IBS-SSS) and the IBS diary	Reduction of scores regarding individual question components (visual analog scale (VAS)) in IBS-SSS. Stool frequency and consistency expressed by Bristol Stool Form Scale in a separate IBS diary.	8 weeks
Secondary	Exploratory responder variables	Satisfactory symptom relief =75% of the time; Reduction in IBS-SSS =50 at end of treatment compared to baseline	8 weeks